RxDoctor Payments Data

William Hoover, MD

Family Medicine · Peru, INNPI 1689602062

Payments from drug & device makers

$1,001in general payments, 2019–2025

Across 60 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$184
  • AbbVie$173
  • GSK$82
  • Abbott$80
  • Regeneron Healthcare Solutions, Inc.$65
  • Lilly USA, LLC$53
  • plus $364 from 15 others

What the payments were for

  • Food & beverage$99199%
  • Education$101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,001 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$185,437
Medicare patients
650
Services billed
4,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide116$160,315
EliquisApixaban391$135,557
XareltoRivaroxaban82$72,002
MounjaroTirzepatide36$50,022
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog102$28,453
JanuviaSitagliptin Phosphate20$26,508
JardianceEmpagliflozin18$24,972
Breo ElliptaFluticasone/Vilanterol48$22,549
TrulicityDulaglutide22$21,755
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$20,168
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$18,067
MyrbetriqMirabegron53$16,031
Lantus SolostarInsulin Glargine,hum.Rec.Anlog121$13,739
Atorvastatin Calcium1,413$11,111
TradjentaLinagliptin63$10,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$50$160,315116 claims
PfizerEliquis$11$135,557391 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Shingrix, Incruse Ellipta$82$76,358176 claims
Lilly USA, LLCMounjaro, Trulicity$53$71,77758 claims
Boehringer IngelheimJardiance, Tradjenta$29$35,60181 claims
MerckJanuvia$27$26,50820 claims
Astellas Pharma US IncMyrbetriq$18$16,03153 claims
AbbVieSavella, Synthroid$173$11,57567 claims
AstraZenecaSymbicort$36$6,39511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Peru

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →